A Comparative Study of Regulations of Nasal Products in the US and EU
A study relating to the regulation for nasal products has been conducted for the current review. The analysis emphasized the significance of classifying nasal products. Nasal products are challenging to manufacture in India due to regulatory and logistical issues. In addition to the production guidelines established by the USFDA and EU, the study analyses the prospects for nasal products in the future. Some common policies held by the 2 major international agencies have been shown in this review.
The current evaluation focuses on how nasal product production should be done in conjunction with other product production and will examine the fundamental recommendations made by the USFDA and EU, as well as whether or not there is a specific category of recommendations for nasal products.
The article demonstrates the USFDA and EU guidelines, and it was found that there were not major differences between the guidelines of the two. Instead, there are only minor differences between the infrastructures of the two agencies related to nasal products.
2. The Benefits of Daily Nasal Sprays. Century Ear, Nose and Throat, Head and Neck Surgery [Internet]. centuryearnosethroat;2022 Jan 12 [cited 2023 Jan 13]. Available from:
3. Touitou E & Illum L. Nasal drug delivery. Drug Delivery and Translational Research. 2012;3(1):1–3.
4. Guidance Document: Statistical Approaches to Establishing Bioequivalence Docket Number: 01D- 0027: Center for Drug Evaluation and Research [Internet]. FDA; 2001 Feb [cited 2023 Jan 12]. Available from:
5. Guidance Document: Nasal Spray and Inhalation Solution, Suspension, and Spray Drug Products--Chemistry, Manufacturing, and Controls Documentation Guidance for Industry July 2002 Docket Number:FDA-1999-D-0060: Center for Drug Evaluation and Research [Internet]. FDA; 2002 Jul [cited 2023 Jan 12]. Available from:
6. Adams WP et al. Demonstrating Bioequivalence of Locally Acting Orally Inhaled Drug Products (OIPs): Workshop Summary Report. J Aerosol Med Pulm Drug Deliv. 2010 Feb;23(1):1-29.
7. Guidance Document: Bioavailability and Bioequivalence Studies for Nasal Aerosols and Nasal Sprays for Local Action (April 2003 Docket Number:FDA-1999-D-0050: Center for Drug Evaluation and Research [Internet]. FDA; 2003 Apr [cited 2023 Jan 15]. Available from:
8. Newman B et al. Scientific and regulatory activities initiated by the U.S. Food and drug administration to foster approvals of generic dry powder inhalers: Bioequivalence perspective. Advanced Drug Delivery Reviews. 2022 Nov; 190: 114526.
9. Adams WP et al. Demonstrating Bioequivalence of Locally Acting Orally Inhaled Drug Products (OIPs): Workshop Summary Report. J Aerosol Med Pulm Drug Deliv. 2010 Feb;23(1):1-29.
10. Velaga, S. P., Djuris, J., Cvijic, S., Rozou, S., Russo, P., Colombo, G., & Rossi, A. Dry powder inhalers: An overview of the in vitro dissolution methodologies and their correlation with the biopharmaceutical aspects of the drug products. European Journal of Pharmaceutical Sciences. 2018;113:18–28
11. Fasiolo, L. T., Manniello, M. D., Tratta, E., Buttini, F., Rossi, A., Sonvico, F., Bortolotti, F., Russo, P., & Colombo, G. Opportunity and challenges of nasal powders: Drug formulation and delivery. European Journal of Pharmaceutical Sciences. 2017; 113:2–17.
12. Henriques, P., Fortuna, A., & Doktorovová, S. Spray dried powders for nasal delivery: Process and formulation considerations. European Journal of Pharmaceutics and Biopharmaceutics. 2022; 176:1-20.
13. Guideline on the requirements for clinical documentation for orally inhaled products (OIP) including the requirements for demonstration of therapeutic equivalence between two inhaled products for use in the treatment of asthma and chronic obstructive pulmonary disease (COPD) in adults and for use in the treatment of asthma in children and adolescents: European Medicines Agency Pre-authorization Evaluation of Medicines for Human Use (CHMP) Doc. Ref.CPMP/EWP/4151/0Rev.1 [Internet]. London: EMEA; 2009 Jan 22 [cited 2023 Jan 11]. Available from:
14. Pallavi Ahirrao, Rushikesh Tambat, Nishtha Chandal, Nisha Mahey et al. MsrA Efflux Pump Inhibitory Activity of L.f. and its Phytoconstituents against RN4220. Chemistry & Biodiversity; 2020.
15. ICH. Choice of control group and related issues in clinical trials [Internet]. US: ICH.org; 2000 Jul 20 [cited 2023 Jan 11]. Available from:
16. Guideline on the Pharmaceutical Quality of Inhalation and Nasal Products. 21 June 2006 Doc Ref.: EMEA/CHMP/QWP/49313/2005 Corr [Internet]. London: European Medicines Agency Inspections; 2006 Oct 01 [cited 2023 Jan 11]. Available from:
17. Lee, S. L., Saluja, B., García- Arieta, A., Santos, G. S., Li, Y., Lu, S., Hou, S., Rebello, J., Vaidya, A., Gogtay, J., Purandare, S. M., & Lyapustina, S. Regulatory Considerations for Approval of Generic Inhalation Drug Products in the US, EU, Brazil, China, and India. Aaps Journal. 2015; 17(5):1285–1304.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The International Journal of Drug Regulatory affairs require a formal written transfer of copyright from the author(s) for each article published. We therefore ask you to complete and return this form, retaining a copy for your records. Your cooperation is essential and appreciated. Any delay will result in a delay in publication.
I/we have read and agree with the terms and conditions stated Page 2 of this agreement and I/we hereby confirm the transfer of all copyrights in and relating to the above-named manuscript, in all forms and media, now or hereafter known, to the International Journal of Drug Regulatory affairs, effective from the date stated below. I/we acknowledge that the IJDRA is relying on this agreement in publishing the above-named manuscript. However, this agreement will be null and void if the manuscript is not published in the IJDRA.
Download link for COPYRIGHT FORM